Literature DB >> 22089244

Acquired Omenn-like syndrome, a novel posttransplant autoaggression syndrome reversed by rapamycin.

Donald C Vinh1, Khalid Bin Dhuban, Helen Mason, Duncan Lejtenyi, Sungmi Jung, Donald C Sheppard, Damien Faury, Nada Jabado, Ciriaco A Piccirillo.   

Abstract

Graft-versus-host disease is uncommon in autologous hematopoietic cell transplantation (HCT) and is typically brief and mild. We report unusual, protracted, and severe Omenn syndrome-like autoaggression following autologous HCT. We identified a profound FOXP3(+) regulatory T cell defect that coincided with hyperinflammatory T cell responses which were reversible with rapamycin in vitro.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22089244      PMCID： PMC3255959          DOI： 10.1128/CVI.05456-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  13 in total

1.  Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma.

Authors:  W R Drobyski; P Hari; C Keever-Taylor; R Komorowski; W Grossman
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

Review 2.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

3.  Omenn syndrome: therapeutic effects of cyclosporin.

Authors:  Sylvan Rego; Andrew Kemp; Melanie Wong; Paul Knight
Journal:  J Paediatr Child Health       Date:  2006-05       Impact factor: 1.954

4.  Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation.

Authors:  A F Hood; G B Vogelsang; L P Black; E R Farmer; G W Santos
Journal:  Arch Dermatol       Date:  1987-06

5.  Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations.

Authors:  Ponpan Matangkasombut; Muriel Pichavant; Doris E Saez; Silvia Giliani; Evelina Mazzolari; Andrea Finocchi; Anna Villa; Cristina Sobacchi; Patricia Cortes; Dale T Umetsu; Luigi D Notarangelo
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

6.  Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

Authors:  Javier Bolaños-Meade; Elizabeth Garrett-Mayer; Leo Luznik; Viki Anders; Jennifer Webb; Ephraim J Fuchs; Carol Ann Huff; William Matsui; Ivan M Borrello; Robert Brodsky; Yvette L Kasamon; Lode J Swinnen; Ian W Flinn; Richard F Ambinder; Richard J Jones; Allan D Hess; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-03       Impact factor: 5.742

7.  Treatment with cyclosporin A in a patient with Omenn's syndrome.

Authors:  A Meyer-Bahlburg; J-P Haas; R Haase; U Eschrich; A Wawer; L Frank; W Ch Marsch; S Burdach; G Horneff
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

8.  Defect of regulatory T cells in patients with Omenn syndrome.

Authors:  Barbara Cassani; Pietro Luigi Poliani; Daniele Moratto; Cristina Sobacchi; Veronica Marrella; Laura Imperatori; Donatella Vairo; Alessandro Plebani; Silvia Giliani; Paolo Vezzoni; Fabio Facchetti; Fulvio Porta; Luigi D Notarangelo; Anna Villa; Raffaele Badolato
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

9.  Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.

Authors:  Manuela Battaglia; Angela Stabilini; Barbara Migliavacca; Jutta Horejs-Hoeck; Thomas Kaupper; Maria-Grazia Roncarolo
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

10.  Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.

Authors:  Paolo Monti; Miriam Scirpoli; Paola Maffi; Lorenzo Piemonti; Antonio Secchi; Ezio Bonifacio; Maria-Grazia Roncarolo; Manuela Battaglia
Journal:  Diabetes       Date:  2008-06-16       Impact factor: 9.461
View more
  1 in total

1.  Case Report: "Primary Immunodeficiency"-Severe Autoimmune Enteropathy in a Pediatric Heart Transplant Recipient Treated With Abatacept and Alemtuzumab.

Authors:  Elizaveta Kalaidina; Elizabeth C Utterson; Deepa Mokshagundam; Mai He; Shalini Shenoy; Megan A Cooper
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.